Phase I/II trial of Velcade [bortezomib] + CHOP-rituximab in patients with previously untreated diffuse large B cell or mantle cell non-Hodgkin's lymphoma

Trial Profile

Phase I/II trial of Velcade [bortezomib] + CHOP-rituximab in patients with previously untreated diffuse large B cell or mantle cell non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 05 Feb 2011 Preliminary results published in the Journal of Clinical Oncology, according to a Millennium: The Takeda Oncology Company media release.
    • 27 Jul 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top